Silexion Therapeutics Reports Q2 2026 Financial Results

What Happened
Silexion Therapeutics Corp. (SLXN) announced its financial results for the second quarter and the six months ended June 30, 2026 in a press release dated August 14, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8‑K (Item 2.02) filed on August 14, 2026; the press release is incorporated by reference into the report.

Key Details

• Press release dated August 14, 2026 titled “Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update” (furnished as Exhibit 99.1).
• Reporting period: second quarter and six months ended June 30, 2026.
• Form 8‑K items reported: Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (exhibits).
• The 8‑K furnishes the company’s earnings/quarterly results and business update; no executive changes, mergers, or other items were reported in this filing.

Why It Matters
This 8‑K signals that Silexion has released its latest quarterly earnings and a business update; investors should review the Exhibit 99.1 press release for specific figures on revenue, net income/loss, cash position, guidance, and operational milestones. Because the 8‑K furnishes (but does not restate) the press release, the exhibit is the primary source for the detailed financial and operational information investors need to assess near‑term performance.